Disulfide-Crosslinked Polyion Micelles for Delivery of Protein Therapeutics

被引:0
作者
Michael J. Heffernan
Niren Murthy
机构
[1] Georgia Institute of Technology,Wallace H. Coulter Department of Biomedical Engineering
来源
Annals of Biomedical Engineering | 2009年 / 37卷
关键词
Drug delivery; Nanocomplex; Polylysine; Ovalbumin; Catalase; CpG-DNA;
D O I
暂无
中图分类号
学科分类号
摘要
New protein delivery systems are needed that efficiently encapsulate proteins and avoid formulation processes that affect protein structure and function. We have developed a protein delivery system termed disulfide-crosslinked polyion micelles (DCPMs), which consist of nanocomplexes formed by electrostatic self-assembly of a protein with a poly(ethylene glycol)-poly(l-lysine) block copolymer (PEG-PLL). The PEG-PLL amines are modified with crosslinkable dithiopyridine groups, using a Michael addition reaction that preserves the positive charges on the PLL chain to optimize polyionic complexation and disulfide crosslinking. DCPMs for vaccine delivery were prepared with ovalbumin and immunostimulatory CpG-DNA and are designed to release the vaccine intracellularly through reduction of disulfide crosslinks. DCPMs were also developed as a long-circulating enzyme carrier that maintains the enzymatic activity of the anti-oxidant enzyme catalase within the micelle core. Ovalbumin and catalase were each modified with SPDP to tether the protein in the micelle core, resulting in a high degree of protein retention under SDS-PAGE. DCPMs efficiently encapsulate and retain functional proteins in a stable polyionic complex and are a versatile delivery system for enzymes, vaccine antigens, and other protein therapeutics.
引用
收藏
页码:1993 / 2002
页数:9
相关论文
共 143 条
  • [1] Bae S. H.(2007)Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy Clin. Cancer Res. 13 341-349
  • [2] Park Y. J.(2007)Enzyme reconstitution/replacement therapy for lysosomal storage diseases Curr. Opin. Pediatr. 19 628-635
  • [3] Park J. B.(2003)Shifting paradigms: biopharmaceuticals versus low molecular weight drugs Int. J. Pharm. 266 3-16
  • [4] Choi Y. S.(2004)Catalytic antioxidants: a radical approach to new therapeutics Drug Discov. Today 9 557-566
  • [5] Kim M. S.(2005)Protein drug stability: a formulation challenge Nat. Rev. Drug Discov. 4 298-306
  • [6] Sin J. I.(2007)Analytical characterisation of glutardialdehyde cross-linking products in gelatine-gum arabic complex coacervates Anal. Chim. Acta 604 45-53
  • [7] Burrow T. A.(2007)Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles J. Biomed. Mater. Res. A 81 652-662
  • [8] Hopkin R. J.(2008)Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity Vaccine 26 5046-5057
  • [9] Leslie N. D.(2006)Peptide crosslinked micelles: a new strategy for the design and synthesis of peptide vaccines Int. J. Nanomedicine 1 97-103
  • [10] Tinkle B. T.(1995)Formation of polyion complex micelles in an aqueous milieu from a pair of oppositely-charged block copolymers with poly(ethylene glycol) segments Macromolecules 28 5294-5299